# Pharma's patent pile-up keeps drug prices high

> Drug makers are filing far more patents on minor tweaks to medicines, delaying cheaper generics and extending monopoly pricing without real innovation.
- Title: Pharma's patent pile-up keeps drug prices high · Ars Technica
- Summary: Drug makers are filing far more patents on minor tweaks to medicines, delaying cheaper generics and extending monopoly pricing without real innovation…
- Keywords: pharmaceutical patents, drug pricing, generic drugs, patent thickets, fda, s. sean tu, united states, healthcare costs, technology, science, Pharma's, patent
- Source: Ars Technica — https://arstechnica.com/health/2026/09/to-keep-drug-prices-high-pharma-has-been-piling-up-the-patents
- Published: 2026-09-28T19:53:37+00:00
- Read time: 1 min
- Topics: pharmaceutical patents, drug pricing, generic drugs, patent thickets, fda, s. sean tu, united states, healthcare costs, technology, science
## Americans pay far more for drugs
Prescription drug costs are a major pain point in US healthcare. Americans pay far more than people in peer countries for the same medicines.
## Patents on drugs have tripled
A study published in JAMA found that patents per small-molecule drug rose from two point one in nineteen ninety to six point nine in two thousand nineteen.
## Most new patents aren't on active ingredients
Eighty four percent of new patents are nonprimary, covering minor tweaks to inactive ingredients, usage updates, or delivery devices like auto-injectors, not the drug's core formula.
## Patent thickets delay generic competition
These extra patents create a patent thicket that delays affordable generics, keeping drug prices higher for longer without actual clinical advances. Patent protection extended from two years in nineteen ninety to six point one years in two thousand nineteen.

> Because patent protection typically determines how long brand-name firms can charge monopoly prices, the rapid growth of nonprimary patents may contribute to limited price competition.
## Drug spending has soared for Americans
Per capita inflation-adjusted spending on prescription drugs rose from two hundred ninety one dollars in nineteen ninety to one thousand eighty four dollars in two thousand nineteen.
## Researchers call for patent reforms
S. Sean Tu and colleagues at the University of Alabama recommend more USPTO scrutiny, laws limiting minor patents, and allowing courts to force drug companies to disgorge profits from patent abuse.
## Without reform, high prices will persist
Without regulatory changes soon, patent thickets will entrench extended monopoly periods disconnected from real innovation and continue delaying generic drug entry to market.

> Will likely entrench extended exclusivity periods that are disconnected from meaningful therapeutic innovation and continue to complicate and delay generic entry.
## Key takeaway

Pharmaceutical companies have tripled patents per drug since nineteen ninety, mostly on minor changes unrelated to active ingredients, extending monopoly pricing and delaying generic competition.